Your browser doesn't support javascript.
loading
Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis.
Pivniouk, Vadim; Gimenes-Junior, Joao A; Ezeh, Peace; Michael, Ashley; Pivniouk, Oksana; Hahn, Seongmin; VanLinden, Sydney R; Malone, Sean P; Abidov, Amir; Anderson, Dayna; Gozdz, Justyna; DeVries, Avery; Martinez, Fernando D; Pasquali, Christian; Vercelli, Donata.
Afiliação
  • Pivniouk V; Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz. Electronic address: vadimp@arizona.edu.
  • Gimenes-Junior JA; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Ezeh P; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Michael A; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Pivniouk O; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Hahn S; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • VanLinden SR; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Malone SP; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Abidov A; Medical Student Research Program, College of Medicine, The University of Arizona, Tucson, Ariz.
  • Anderson D; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • Gozdz J; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
  • DeVries A; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz.
  • Martinez FD; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz.
  • Pasquali C; OM Pharma SA, Geneva, Switzerland.
  • Vercelli D; Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz; Arizona Center for the Biology of Complex Diseases, The University of A
J Allergy Clin Immunol ; 149(3): 943-956, 2022 03.
Article em En | MEDLINE | ID: mdl-34560105
BACKGROUND: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma. OBJECTIVES: We sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route. METHODS: Different strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85-treated dendritic cells protect allergen-sensitized, OM-85-naive mice against asthma. RESULTS: Airway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85-induced asthma protection. CONCLUSIONS: We provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27- to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Interleucina-33 Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Interleucina-33 Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2022 Tipo de documento: Article